Rob van Maanen

Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)

Paul Abrams, Con Kelleher, David Staskin et al. · European Urology · 2014 · 244 citations

Urological Research, Urology, Voiding Dysfunction +7

Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder ( <scp>SYNERGY</scp> study)

Sender Herschorn, Christopher R. Chapple, Paul Abrams et al. · British Journal of Urology · 2017 · 171 citations · Full text

Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II)

Christian Gratzke, Rob van Maanen, Christopher R. Chapple et al. · European Urology · 2018 · 107 citations · Full text

Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with <i>Clostridioides (Clostridium) difficile</i> Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE)

Joshua Wolf, Krisztina Kalocsai, Clàudia Fortuny et al. · Clinical Infectious Diseases · 2019 · 80 citations · Full text

Patient‐reported outcomes from SYNERGY, a randomized, double‐blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients

Dudley Robinson, Con Kelleher, David Staskin et al. · Neurourology and Urodynamics · 2017 · 37 citations